What pension research reveals about retirement planning

As the cost of living crisis eases, what steps are you taking to build your pension?

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

79.18

+2.07

(+2.68%)

At close: 04:00PM EDT

79.24

+0.06

(+0.08%)

After hours:

04:23PM EDT

Trade prices are not sourced from all markets

Press releases

Business Wire
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England, May 21, 2024--Investor Day 2024
Business Wire
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
GlobeNewswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasda